227 related articles for article (PubMed ID: 24835790)
1. Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma.
Martin JW; Chilton-MacNeill S; Koti M; van Wijnen AJ; Squire JA; Zielenska M
PLoS One; 2014; 9(5):e95843. PubMed ID: 24835790
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.
Sadikovic B; Thorner P; Chilton-Macneill S; Martin JW; Cervigne NK; Squire J; Zielenska M
BMC Cancer; 2010 May; 10():202. PubMed ID: 20465837
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.
Yoshida A; Ushiku T; Motoi T; Beppu Y; Fukayama M; Tsuda H; Shibata T
Am J Surg Pathol; 2012 Mar; 36(3):423-31. PubMed ID: 22301501
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma.
Mejia-Guerrero S; Quejada M; Gokgoz N; Gill M; Parkes RK; Wunder JS; Andrulis IL
Genes Chromosomes Cancer; 2010 Jun; 49(6):518-25. PubMed ID: 20196171
[TBL] [Abstract][Full Text] [Related]
5. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.
Roos A; Satterfield L; Zhao S; Fuja D; Shuck R; Hicks MJ; Donehower LA; Yustein JT
Br J Cancer; 2015 Nov; 113(9):1289-97. PubMed ID: 26528706
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and CDK4 expression in periosteal osteosarcoma.
Righi A; Gambarotti M; Benini S; Gamberi G; Cocchi S; Picci P; Bertoni F
Hum Pathol; 2015 Apr; 46(4):549-53. PubMed ID: 25680902
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
Lu XY; Lu Y; Zhao YJ; Jaeweon K; Kang J; Xiao-Nan L; Ge G; Meyer R; Perlaky L; Hicks J; Chintagumpala M; Cai WW; Ladanyi M; Gorlick R; Lau CC; Pati D; Sheldon M; Rao PH
Mol Cancer Res; 2008 Jun; 6(6):937-46. PubMed ID: 18567798
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
Jia F; Zhang Z; Zhang X
J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
[TBL] [Abstract][Full Text] [Related]
9. 12q amplification defines a subtype of extraskeletal osteosarcoma with good prognosis that is the soft tissue homologue of parosteal osteosarcoma.
Kyriazoglou AI; Vieira J; Dimitriadis E; Arnogiannaki N; Teixeira MR; Pandis N
Cancer Genet; 2012 Jun; 205(6):332-6. PubMed ID: 22749040
[TBL] [Abstract][Full Text] [Related]
10. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas.
Wunder JS; Eppert K; Burrow SR; Gokgoz N; Bell RS; Andrulis IL
Oncogene; 1999 Jan; 18(3):783-8. PubMed ID: 9989829
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
Skomedal H; Kristensen GB; Lie AK; Holm R
Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
[TBL] [Abstract][Full Text] [Related]
12. Gene amplification and tumor grading in parosteal osteosarcoma.
Chen PC; Yen CC; Hung GY; Pan CC; Chen WM
J Chin Med Assoc; 2019 Dec; 82(12):889-894. PubMed ID: 31634336
[TBL] [Abstract][Full Text] [Related]
13. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses.
Salinas-Souza C; De Oliveira R; Alves MT; Garcia Filho RJ; Petrilli AS; Toledo SR
Hum Pathol; 2013 Oct; 44(10):2188-98. PubMed ID: 23845465
[TBL] [Abstract][Full Text] [Related]
14. The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.
Limbach AL; Lingen MW; McElherne J; Mashek H; Fitzpatrick C; Hyjek E; Mostofi R; Cipriani NA
Head Neck Pathol; 2020 Dec; 14(4):889-898. PubMed ID: 32026294
[TBL] [Abstract][Full Text] [Related]
15. RECQ DNA helicases and osteosarcoma.
Lu L; Jin W; Liu H; Wang LL
Adv Exp Med Biol; 2014; 804():129-45. PubMed ID: 24924172
[TBL] [Abstract][Full Text] [Related]
16. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
17. Gnathic giant-cell-rich conventional osteosarcoma with MDM2 and CDK4 gene amplification.
Hirose K; Okura M; Sato S; Murakami S; Ikeda JI; Noda Y; Fukuda Y; Morii E; Toyosawa S
Histopathology; 2017 Jun; 70(7):1171-1173. PubMed ID: 27926798
[No Abstract] [Full Text] [Related]
18. CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcoma.
Iwata S; Tatsumi Y; Yonemoto T; Araki A; Itami M; Kamoda H; Tsukanishi T; Hagiwara Y; Kinoshita H; Ishii T; Nagase H; Ohira M
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036394
[TBL] [Abstract][Full Text] [Related]
19. [Bioinformatics-based identification of key genes CDC5L and related pathways in osteosarcoma and Ewing's sarcoma].
Feng N; Song WX; Shao LP; Gao YH; Zhao CW
Zhongguo Gu Shang; 2022 Mar; 35(3):276-80. PubMed ID: 35322620
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma in blood relatives.
Longhi A; Benassi MS; Molendini L; Macchiagodena M; Picci P; Bacci G
Oncol Rep; 2001; 8(1):131-6. PubMed ID: 11115584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
